Brainstorm Cell Therapeutics Unveils Robust Q2 2025 Financials and Pivotal Clinical Advancements

Brainstorm Cell Therapeutics (NASDAQ: BCLI), a pioneering force in the development of adult stem cell technologies for neurodegenerative diseases, recently announced its financial results for the second quarter ended June 30, 2025, alongside an encouraging corporate update. The company continues to make significant strides in its mission to bring innovative therapies to patients, particularly with its flagship NurOwn® program for Amyotrophic Lateral Sclerosis (ALS).Highlighting the financial overview, Brainstorm reported cash and cash equivalents of $14.5 million as of June 30, 2025, compared to $18.2 million at December 31, 2024.Research and development (R&D) expenses for the second quarter of 2025 were $3.8 million, a slight decrease from $4.1 million in the same period of 2024.

This reflects efficient resource allocation while maintaining a strong focus on clinical progress. General and administrative (G&A) expenses stood at $2.1 million for Q2 2025, consistent with the $2.0 million reported in Q2 2024.The net loss for the quarter was $5.9 million, or $0.18 per share, improving from a net loss of $6.0 million, or $0.20 per share, in the comparable period of 2024.Beyond the numbers, the corporate update provided a compelling picture of progress.

Brainstorm is actively preparing for the potential resubmission of its Biologics License Application (BLA) for NurOwn® for ALS, following constructive discussions with the U.S.Food and Drug Administration (FDA). The company has indicated that the resubmission strategy will incorporate additional analyses of existing clinical trial data, aiming to further elucidate NurOwn's therapeutic benefits and address previous regulatory feedback.

This ongoing dialogue with the FDA underscores Brainstorm’s commitment to navigating the regulatory landscape with diligence and scientific rigor.Furthermore, Brainstorm continues to explore strategic partnerships and funding opportunities to bolster its financial runway and accelerate the development of NurOwn® and its broader pipeline.The company’s leadership expressed confidence in the scientific foundation of NurOwn® and its potential to significantly impact the lives of individuals living with ALS, a devastating neurodegenerative condition with limited treatment options.

The team remains dedicated to advancing this promising therapy through the final stages of regulatory review and towards commercialization, bringing hope to patients and their families...